In a 12-week trial, oat β-glucan tablets did not lower LDL (“bad”) cholesterol, and higher doses caused more stomach side effects.

Objective
To evaluate the efficacy and safety of a high–medium molecular weight β-glucan tablet (1.5, 3, or 6 g/day) in reducing LDL cholesterol and other lipid subfractions in adults with hyperlipidemia (LDL-C >3.37 mmol/L), some of whom were on statin therapy. 

Methods

• Design: Randomized, double-blind, placebo-controlled, parallel-group clinical trial.
• Population: 263 adults with hyperlipidemia; 66 participants assigned to each β-glucan dose group and 65 to placebo.
• Intervention: Daily oral tablet containing β-glucan at 1.5 g, 3 g, or 6 g versus matching placebo for 12 weeks.
• Primary endpoint: Change in serum LDL cholesterol from baseline to week 12.
• Secondary endpoints: Changes in total cholesterol, small LDL cholesterol subclass particle concentration, non–HDL cholesterol, apolipoprotein B, VLDL cholesterol, and high-sensitivity C-reactive protein (hs-CRP), plus safety outcomes.
• Mechanisms/pathways: The trial was motivated by prior clinical evidence that oat-soluble fiber β-glucan may have lipid-lowering effects, but no mechanistic biomarkers or pathways (e.g., bile acid handling, intestinal effects) were directly assessed in this study.

Results

• Primary outcome (LDL-C):
  • Mean change from baseline to 12 weeks in LDL-C:
    • β-glucan 1.5 g/day: +0.08 mmol/L (P = 0.23 vs placebo)
    • β-glucan 3 g/day: +0.11 mmol/L (P = 0.18 vs placebo)
    • β-glucan 6 g/day: −0.04 mmol/L (P = 0.72 vs placebo)
    • Placebo: −0.10 mmol/L
  • None of the β-glucan doses produced a statistically significant LDL-C reduction compared with placebo.
• Secondary lipid and inflammatory markers:
  • No significant between-group differences were observed for total cholesterol, small LDL cholesterol subclass particle concentration, non–HDL-C, apoB, VLDL-C, or hs-CRP.
• Safety and adverse events:
  • Gastrointestinal (GI) adverse events were common across all groups:
    • Reported in 23.4%, 34.8%, and 66.7% of participants in the three β-glucan groups, and 36.9% in the placebo group.
    • Overall comparison across the four groups was statistically significant (P < 0.0001), suggesting dose-related or formulation-related GI tolerability issues at higher β-glucan exposure.
  • No mention of severity, specific GI symptoms, or discontinuation rates.

Interpretation

Under the conditions of this 12-week trial, a tablet formulation of high–medium molecular weight β-glucan at doses up to 6 g/day did not provide additional LDL-C lowering beyond placebo in adults with elevated LDL-C, despite the background rationale that β-glucan as oat-soluble fiber may lower lipids.

The absence of signal across multiple lipid subfractions (total cholesterol, non–HDL-C, apoB, VLDL, small LDL) and hs-CRP supports a consistent null effect for this product and dosing regimen.

Mechanisms & pathways 
Rationale centers on viscosity-mediated intestinal actions such as bile-acid binding, decreased cholesterol/bile reabsorption, and upregulation of hepatic LDL receptors, which depend on β-glucan molecular weight and processing. The authors note that depolymerization during extraction/processing can reduce MW/viscosity, potentially blunting lipid-lowering. 

Although β-glucan is framed as a soluble fiber with presumed lipid-lowering properties, the study did not include mechanistic or pharmacodynamic markers to clarify why the expected effect was not observed (e.g., no direct assessment of absorption, bile acid metabolism, or changes in lipoprotein profiles beyond standard subfractions).

Dosages & adverse reactions

• Dose arms: 1.5, 3, or 6 g/day of oat β-glucan tablets for 12 weeks (TID dosing pattern).
• Product characteristics: 400–700 kDa average MW (range 40–2500 kDa).
• Adverse events: Dose-related GI symptoms; no consistent lipid benefits at any dose.

Quality of study (assessment)
Strengths: Multicenter RCT, double-blind; central lab; adequate planned sample size; ITT and per-protocol analyses; comprehensive lipid panel; prespecified subgroups.

Limitations: No dietary diaries/lead-in; compliance assessed by bottle return with TID dosing burden; wide MW variability and no viscosity verification of the tablet; low statin and low diabetes prevalence limiting synergy analyses; may be underpowered for small LDL-C differences (<0.30 mmol/L); findings apply to this tablet formulation rather than food-based β-glucan.

Implications
For patients with hyperlipidemia, oat β-glucan in tablet form (1.5–6 g/day) did not improve LDL-C or other lipid measures over 12 weeks and produced more GI AEs at higher doses. If β-glucan is considered for lipid management, food-based, high-viscosity formulations with verified MW/viscosity (and concurrent diet/lifestyle optimization) are likely more appropriate than this specific tablet product; future trials should standardize MW/viscosity, include mechanistic endpoints, and ensure dietary control.